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azole for 1-161 days (median 7). The length of voriconazole ther-
apy was 6-956 days (median 120). The total number of patient-days
on voriconazole was 14,000d. A total of 10 IFIs were seen in
patients on voriconazole: Candida glabrata (n5), Candida krusei
(n1), Cunninghamella (n1), Rhizopus (n2), and Mucor
(n1).Although 4 cases of zygomycosis were seen, no case of
Aspergillus infection was seen. The actuarial probability of zygo-
mycosis or any invasive fungal infection is 7% and 18% respec-
tively.
Zygomycetes are not susceptible to voriconazole, and break-
through infections are not surprising. In clinical trials C. glabrata
and C. krusei were susceptible to voriconazole at MIC90.5-2mcg
and the majority of ﬂuconazole resistant C.Glabrata isolates have
MIC90s1mcg.dose. Interestingly, steady-state trough voricon-
azole levels were 0.2, 0.2, 0.33, 0.55, 0.63, and 1.78 mcg/mL in
the 6 candidiasis cases. C.Glabrata in patient with vori level1.78
was ﬂuconazole resistant(c/s not avaiable for other Candida spec-
imens). All 6 candidiasis cases were seen amongst the 44 patients
when voriconazole levels  2 mcg and none amongst the 36 with
levels of 2 mcg (P0.061; Fishers exact test), consistent with a
study correlating voriconazole levels and clinical success in as-
pergillosis (Smith et al. Antimicrob Agents Chemother 2006;50:
1570-1572).
Voriconazole is extremely effective in preventing aspergillus in-
fections but Zygomycosis remains a concern in voriconazole-
treated patients. Therapeutic drug monitoring with dose adjust-
ment may be indicated in patients on voriconazole to avoid
infections with fungi that are otherwise susceptible to the drug.
breakthrough infections
Organism Site
Days of
exposure to
voriconazole
Days post
transplant
Concommitant
infection/neutropenia GVHD
Number of
days of prior
exposure to
itraconazole
Voriconazole
level
C.Krusei lung 157 183 E.coli and VRE/no GI 26 0.53
C.Glabrata lung 136 145 VRE/yes GI 9 0.63
C.Glabrata lung 832 837 MRSE/yes GI/Skin 7 0.20
C.Glabrata lung 159 179
MRSA and
Enterobacter/yes GI/Skin 20 1.78
C.Glabrata lung 56 137 MRSA and Strept/yes GI/Skin 122 0.33
C.Glabrata lung 7 9 VRE/yes GI/Skin 7 0.33
Rhizopus sinus 128 135 VRE/no Skin 7 4.1
Rhizopus lung 7 55 none/no none 128 5.9
Mucor lung 77 77 E.coli/no Skin 0 3.5
Cunninghamella lung 17 90 CONS/yes GI 64 1.1
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There is limited data on the effects of drug levels on therapeutic
success in fungal infections. A signiﬁcant correlation between
plasma voriconazole levels(2) and successful Aspergillosis out-
comes was reported.(Smith et al.Antimicob Agents Chemother
2006;(50):1570-2). Pharmacodynamic studies as well as recently
proposed CSLI voriconazole breakpoints suggest a need for ther-
apeutic monitoring. Multiple drugs used during HSCT can affect
the liver cytochrome P450 system, which plays a signiﬁcant role in
voriconazole metabolism. Likewise, voriconazole also exhibits ge-
netic polymorphism. Extensive metabolizers have a signiﬁcantly
lower exposure to voriconazole than poor metabolizers. In a small
trial including 22 patients (Triﬁlio et.al.BMT 2005(5)509) wide
interpatient variablilty in plasma voriconazole levels was reported
for patients receiving equivalent doses of voriconazole, many with
levels below the MIC(90) for Candida and Aspergillus.
In this study, steady-state plasma trough voriconazole levels were
measured after at least 5 days of therapy in 94 patients after HSCT
on 208 separate occassions (median2;range1-5). Most patients
had undergone allogeneic HSCT. Plasma voriconazole levels were
measured using standard HPLC method. The daily voriconazole
dose was 200 mg (n4), 400 mg (n157), 500 mg (n20), 600 mg
(n19), and 800 mg (n8);corresponding to 2.0-16.3 mg/kg (me-
dian 5.4). The voriconazole levels were 0.2-12.5 mcg/mL (me-
dian 1.2). In keeping with the non-linear pharmacokinetic proﬁle
of the drug, a strong correlation was not seen between the dose and
levels.
(P.05)
The table below shows the relationships between levels and dose.
While the amount of drug administered in mg//kg was signiﬁcantly
higher when levels were  5mcg/ml, there was no consistent
relationship between dose and level below that threshold (P val-
ue0.05).
We conclude that adult patients receiving standard doses of
voriconazole have highly variable drug levels. Over 37% of the
voriconazole levels were below the suggested breakpoints for C.G-
labrata and C.Krusei , and over 60% would be associated with a
greater likelihood of failure for Aspergillus infection. Future vori-
conazole studies should include therapeutic drug monitoring, and
until this is clariﬁed, patients should be monitored especially for
those with conﬁrmed life-threatening infections.
Voriconazole levels and dose
Voriconazole
dose/day(mg) n
median
voriconazole
level (range)
average
dose
(mg/kg)
percent of
levels
<0.5mcg
percent of
levels
<1.0mcg
percent of
levels <
2.0mcg
200 4 1.66 (0-3.07) 3.3 25 25 50
400 157 1.09 (0-11.1) 5.2 28 45 65
500 20 1.66 (0-5.99) 6.3 20 40 55
600 19 1.5 (0-6.75) 8.9 21 31 58
800 9 2.06 (0-12.5) 10.8 33 33 50
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